Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology
K Ratnam, JA Low - Clinical Cancer Research, 2007 - AACR
Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme that signals the presence of DNA
damage by catalyzing the addition of ADP-ribose units to DNA, histones, and various DNA …
damage by catalyzing the addition of ADP-ribose units to DNA, histones, and various DNA …
The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment
I Caro, JA Low - Clinical Cancer Research, 2010 - AACR
The hedgehog (Hh) signaling pathway plays an important role in embryogenesis across
multiple species. Its activity is reduced or absent in adult organisms. However, activation of the …
multiple species. Its activity is reduced or absent in adult organisms. However, activation of the …
[HTML][HTML] Efficacy and safety of vismodegib in advanced basal-cell carcinoma
…, CM Rudin, ALS Chang, JA Low… - … England Journal of …, 2012 - Mass Medical Soc
Background Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell
carcinoma. Although most basal-cell carcinomas are treated surgically, no effective …
carcinoma. Although most basal-cell carcinomas are treated surgically, no effective …
[HTML][HTML] Inhibition of the hedgehog pathway in advanced basal-cell carcinoma
…, JC Marsters Jr, FJ De Sauvage, JA Low - … England Journal of …, 2009 - Mass Medical Soc
Background Mutations in hedgehog pathway genes, primarily genes encoding patched
homologue 1 (PTCH1) and smoothened homologue (SMO), occur in basal-cell carcinoma. In a …
homologue 1 (PTCH1) and smoothened homologue (SMO), occur in basal-cell carcinoma. In a …
[HTML][HTML] Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449
…, DD Von Hoff, FJ De Sauvage, JA Low - … England Journal of …, 2009 - Mass Medical Soc
<p id="p001">Medulloblastoma is the most common malignant brain tumor in children. Aberrant
activation of the hedgehog signaling pathway is strongly implicated in the development …
activation of the hedgehog signaling pathway is strongly implicated in the development …
Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
…, Z Kan, S Seshagiri, CL Hann, SE Gould, JA Low… - Science, 2009 - science.org
The Hedgehog (Hh) signaling pathway is inappropriately activated in certain human cancers,
including medulloblastoma, an aggressive brain tumor. GDC-0449, a drug that inhibits Hh …
including medulloblastoma, an aggressive brain tumor. GDC-0449, a drug that inhibits Hh …
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam, JA Low, SX Yang, CK Chow… - Journal of Clinical …, 2006 - ascopubs.org
Purpose Vascular endothelial growth factor (VEGF) is a potent molecule that mediates tumor
angiogenesis primarily through VEGF receptor 2 (VEGFR2). Bevacizumab, a recombinant …
angiogenesis primarily through VEGF receptor 2 (VEGFR2). Bevacizumab, a recombinant …
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
…, WC Darbonne, RA Graham, KL Zerivitz, JA Low… - Clinical cancer …, 2011 - AACR
Purpose: The hedgehog (Hh) signaling pathway, a key regulator of cell growth and
differentiation during development is implicated in pathogenesis of certain cancers. Vismodegib (…
differentiation during development is implicated in pathogenesis of certain cancers. Vismodegib (…
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
…, D Morosini, BB Tuch, M Fernandes, N Nanda, JA Low - Cancer discovery, 2015 - AACR
Oncogenic TRK fusions induce cancer cell proliferation and engage critical cancer-related
downstream signaling pathways. These TRK fusions occur rarely, but in a diverse spectrum of …
downstream signaling pathways. These TRK fusions occur rarely, but in a diverse spectrum of …
[HTML][HTML] Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
…, LR Phillips, J Ji, A Monks, JA Low… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose We conducted the first phase 0 clinical trial in oncology of a therapeutic agent
under the Exploratory Investigational New Drug Guidance of the US Food and Drug …
under the Exploratory Investigational New Drug Guidance of the US Food and Drug …